<DOC>
	<DOCNO>NCT00728858</DOCNO>
	<brief_summary>Nifedipine barnidipine act calcium channel blocker , widely prescribed pressure control prehypertension stage 1 hypertension . CYP3A4 responsible metabolism nifedipine nifedipine , contribution CYP3A5 remain ambiguous . This study aim analyze association antihypertensive effect nifedipine well barnidipine single nucleotide polymorphism CYP3A4 , CYP3A5 calcium channel .</brief_summary>
	<brief_title>The Efficacy , Safety Genetic Polymorphism Hypoca Adalat OROS Hypertensive Patients</brief_title>
	<detailed_description>For drug , 20 patient enrol . Patients ' blood pressure heart rate measure first visit , follow visit week4 , week 8 week 12 . Blood sample draw week 4 week 12 following analysis drug plasma concentration . SNPs CYP3A4 , CYP3A5 calcium channel v 1.2 genotyped use SNPstream . The difference decrease blood pressure durg plasma concentration genotype analyze .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>20~90 year old patient mild moderate hypertensive patient finish study sign agreement severe hypertension Heart failure , Arrhythmia Liver kidney failure pregnant woman allergy dihydropyridines attend clinical trial past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>87 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>SNP</keyword>
	<keyword>Nifedipine</keyword>
	<keyword>Barnidipine</keyword>
</DOC>